ConductScience.org, home

Paper6843516

Radiation dose enhancement in tumors with iodine.

Santos Mello R and 4 others. Med Phys, 1983. Cited by 117 papers, by iCite.

Cite this record

ConductScience Library. Radiation dose enhancement in tumors with iodine. Papers, record 6843516. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6843516

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Radiation dose enhancement in tumors with iodine.
PubMed
Journal
Med Phys
PubMed
Year
1983
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
117
iCite
Relative citation ratio, by iCite
3.48
iCite
Revised in PubMed
2017-02-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Santos Mello RR
2Callisen HH
3Winter JJ
4Kagan ARA R
5Norman AA

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Contrast MediaMajor topic
DiatrizoateMajor topic
NeoplasmsMajor topic
Radiotherapy DosageMajor topic
Animals
Brain Neoplasms
Chromosome Aberrations
Female
Glioma
Humans
Lymphocytes
Mice
Neoplasms, Experimental
Rabbits

Source PubMed

Download CSV of topics

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 117 citations.

PMIDTitleJournalYearIn PapersSource
41865179From Marker to Modulator: Lipiodol-Mediated Dose Enhancement in Liver Tumor Radiotherapy.Cardiovasc Intervent Radiol2026https://conductscience.org/library/papers/41865179PubMed
41692835Lipiodol-Mediated Dose Enhancement in Radiation Therapy: A Phantom and In Vitro Study in Hepatocellular Carcinoma.Cardiovasc Intervent Radiol2026https://conductscience.org/library/papers/41692835PubMed
39611766Enhancing targeted doses: Low-energy photon lipiodol-enhanced radiotherapy (LEPERT) for liver cancer patients.J Appl Clin Med Phys2025https://conductscience.org/library/papers/39611766PubMed
39014282Enhanced radio-photodynamic therapy potential of advanced gold-based nanoclusters for breast cancer treatment.Radiol Phys Technol2024https://conductscience.org/library/papers/39014282PubMed
38893315Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment.Molecules2024https://conductscience.org/library/papers/38893315PubMed
37781236Dual enhancement in the radiosensitivity of prostate cancer through nanoparticles and chemotherapeutics.Cancer Nanotechnol2023https://conductscience.org/library/papers/37781236PubMed
37686211Study of Nuclear Reactions in Therapy of Tumors with Proton Beams.Int J Mol Sci2023https://conductscience.org/library/papers/37686211PubMed
37555747Prospects of nanoparticle-based radioenhancement for radiotherapy.Mater Horiz2023https://conductscience.org/library/papers/37555747PubMed
36816996Synthesis and characterization of actively HER-2 Targeted Fe3O4@Au nanoparticles for molecular radiosensitization of breast cancer.Bioimpacts2023https://conductscience.org/library/papers/36816996PubMed
36559288Repurposing Antimalarial Pyronaridine as a DNA Repair Inhibitor to Exploit the Full Potential of Gold-Nanoparticle-Mediated Radiation Response.Pharmaceutics2022https://conductscience.org/library/papers/36559288PubMed
35835744Breaking photoswitch activation depth limit using ionising radiation stimuli adapted to clinical application.Nat Commun2022https://conductscience.org/library/papers/35835744PubMed
35335886Iodine Nanoparticles (Niodx™) for Radiotherapy Enhancement of Glioblastoma and Other Cancers: An NCI Nanotechnology Characterization Laboratory Study.Pharmaceutics2022https://conductscience.org/library/papers/35335886PubMed
34575482Gold-Protein Composite Nanoparticles for Enhanced X-ray Interactions: A Potential Formulation for Triggered Release.Pharmaceutics2021https://conductscience.org/library/papers/34575482PubMed
33101867Radiation Dose-Enhancement Is a Potent Radiotherapeutic Effect of Rare-Earth Composite Nanoscintillators in Preclinical Models of Glioblastoma.Adv Sci (Weinh)2020https://conductscience.org/library/papers/33101867PubMed
32973267Iodine nanoparticle radiotherapy of human breast cancer growing in the brains of athymic mice.Sci Rep2020https://conductscience.org/library/papers/32973267PubMed
30872755Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy.Sci Rep2019https://conductscience.org/library/papers/30872755PubMed
30218059Small, Long Blood Half-Life Iodine Nanoparticle for Vascular and Tumor Imaging.Sci Rep2018https://conductscience.org/library/papers/30218059PubMed
28287916The Effect of Contrast Material on Radiation Dose at CT: Part II. A Systematic Evaluation across 58 Patient Models.Radiology2017https://conductscience.org/library/papers/28287916PubMed
27446499Standards and Methodologies for Characterizing Radiobiological Impact of High-Z Nanoparticles.Theranostics2016https://conductscience.org/library/papers/27446499PubMed
27255899Synergistic Effects of Gold Nanocages in Hyperthermia and Radiotherapy Treatment.Nanoscale Res Lett2016https://conductscience.org/library/papers/27255899PubMed

See all 31 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6843516

GET https://conductscience.org/api/papers/v1/6843516/cited_by?page=2